<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01215890</url>
  </required_header>
  <id_info>
    <org_study_id>RIS-RF</org_study_id>
    <nct_id>NCT01215890</nct_id>
  </id_info>
  <brief_title>Risedronate Therapy in the Treatment of Low Bone Mineral Density in Crohn's Disease</brief_title>
  <official_title>A Randomized, Data Collection Program To Determine the Efficacy and Safety of Risedronate (Actonel) Therapy Plus Calcium and Vitamin D Supplementation Versus Placebo Plus Calcium and Vitamin D Supplementation in the Treatment of Low Bone Mineral Density in Crohn's Disease Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alberta</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Alberta</source>
  <brief_summary>
    <textblock>
      The occurrence of bone loss in Crohn's disease patients is an important clinical problem for&#xD;
      both patients with and without active disease. While therapy does exist for treatment and&#xD;
      prevention of low BMD, evidence of its efficacy in Crohn's disease patients is lacking. The&#xD;
      current standard of therapy in Canada for the treatment of osteoporosis is etidronate, with&#xD;
      adequate calcium and vitamin D supplementation.&#xD;
&#xD;
      The primary objective of the study is to assess the efficacy of risedronate, compared to&#xD;
      placebo, administered once-weekly, in the treatment of low BMD of the spine and hip in&#xD;
      patients with Crohn's disease at 12 months, based on an intention-to-treat analysis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <number_of_arms>2</number_of_arms>
  <condition>Crohn's Disease</condition>
  <condition>Low Bone Mineral Density</condition>
  <arm_group>
    <arm_group_label>risedronate plus calcium and viamin D</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo plus clacium and vitamin D</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>risedronate</intervention_name>
    <arm_group_label>risedronate plus calcium and viamin D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>placebo plus clacium and vitamin D</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects who are 18 years of age, or older.&#xD;
&#xD;
          -  Crohn's disease, as documented by clinical, radiologic, endoscopic or histologic&#xD;
             examination.&#xD;
&#xD;
          -  Osteoporosis (T score less than -2.5) or osteopenia (T score between -1.0 and -2.5),&#xD;
             as determined by dual energy X-ray absorptiometry.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known bone disorders other than osteoporosis (such as hyperparathyroidism, Paget's&#xD;
             disease, renal osteodystrophy and documented osteomalacia)&#xD;
&#xD;
          -  Abnormal thyroid function. Those patients on thyroxine replacement must not have had a&#xD;
             change in dose in the two months prior to prospective data collection program entry&#xD;
&#xD;
          -  Clinically significant renal impairment (serum creatinine â‰¥ 2x normal).&#xD;
&#xD;
          -  Clinical Short Bowel Syndrome&#xD;
&#xD;
          -  Patients on total parenteral or enteral nutrition&#xD;
&#xD;
          -  Spinal anatomy that would not allow adequate assessment of lateral spine using DEXA&#xD;
&#xD;
          -  Patients who had received:&#xD;
&#xD;
               1. previous bisphosphonate therapy&#xD;
&#xD;
               2. fluoride supplement in the 24 months prior to entry&#xD;
&#xD;
               3. calcium supplements of more than 1.0g/day in the 6 months prior to entry&#xD;
&#xD;
               4. vitamin D supplements greater than 1000 IU/day in the 6 months prior to entry&#xD;
&#xD;
               5. calcitonin in the 3 months prior to entry&#xD;
&#xD;
          -  Females on hormone replacement therapy who do not agree to continue the therapy for&#xD;
             the duration of the prospective data collection program&#xD;
&#xD;
          -  Men on testosterone who do not agree to continue it for the duration of the&#xD;
             prospective data collection program&#xD;
&#xD;
          -  Pregnancy or women who are breastfeeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard Fedorak, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alberta</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Gastrointestinal and Liver Disease Research (GILDR) Group</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G-2X8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>October 2010</verification_date>
  <study_first_submitted>October 5, 2010</study_first_submitted>
  <study_first_submitted_qc>October 5, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 7, 2010</study_first_posted>
  <last_update_submitted>October 5, 2010</last_update_submitted>
  <last_update_submitted_qc>October 5, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 7, 2010</last_update_posted>
  <keyword>Crohn's disease</keyword>
  <keyword>Low bone mineral density</keyword>
  <keyword>inflammatory bowel disease</keyword>
  <keyword>bisphosphonate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bone Diseases, Metabolic</mesh_term>
    <mesh_term>Crohn Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Risedronic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

